Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Should a comparison be made between Bioasis and Denali?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(751)
•••
Comment by Finallytherockon Dec 22, 2020 7:59pm
199 Views
Post# 32166529

RE:RE:RE:RE:RE:Should a comparison be made between Bioasis and Denali?

RE:RE:RE:RE:RE:Should a comparison be made between Bioasis and Denali?i think it makes some sense to compare us to dnli given we are in a similar space and it appears, at least right now, our platform is better. we can look at their market cap and dream that if our platform is truly better, where can this stock price go? i know there are some here who are frustrated. i get it. i owned this one years ago and sold because progress was so slow but i jumped in once we signed the chiasi deal because then i knew our platform finally had some validity and we had a big pharma steering the ship a bit. if this platform was as great as we believe, chiasi, at least, would bring it to fruition, i hold over 700K shares.  i am heavily invested here as i believe in the platform. dr rathjen recently stated on her podcast we will see data which will help promote partnerships in the first quarter. at this point, the best thing is just to wait and see. we are not that far off from seeing the data and since she was so emphatic about the data coming out first quarter, i can't imagine there will be more delays
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities